BNT162b2 mRNA COVID-19 Vaccine Effectiveness in the Prevention of SARS-CoV-2 Infection: A Preliminary Report
BNT162b2 mRNA COVID-19 Vaccine Effectiveness in the Prevention of SARS-CoV-2 Infection: A Preliminary Report
复制标题
DOI：
10.1093/infdis/jiab262
复制
发表时间：
2021-06-22
影响因子：
6.4
通讯作者：
Stefanizzi, Pasquale
中科院分区：
文献类型：
--
作者：
Bianchi, Francesco Paolo;Germinario, Cinzia Annatea;Stefanizzi, Pasquale
在注册前试验中，未收集BNT 162 b2 mRNA疫苗对SARS-CoV-2感染的有效性数据。本研究旨在评价疫苗对记录感染的有效性（VE）。将完成疫苗接种计划的巴里Policlinico大学医院卫生保健工作者（HCW）与拒绝接种疫苗的HCW进行匹配。首次给药后14-20天，记录的感染的VE为61.9%（95%置信区间[CI]，19.2%-82.0%），首次给药后21-27天为87.9%（95% CI，51.7%-97.0%），第二次给药后7天或以上为96.0%（95% CI，82.2%-99.1%）。未接种疫苗的医务工作者在大流行紧急情况下仍然是一个令人关切的问题。
In the preregistration trial, data on efficacy of BNT162b2 mRNA vaccine against SARS-CoV-2 infection were not collected. This study aimed to evaluate vaccine effectiveness (VE) against documented infection. Bari Policlinico University Hospital health care workers (HCWs) who completed the vaccination schedule were matched with HCWs who had refused vaccination. VE for documented infection was 61.9% (95% confidence interval [CI], 19.2%-82.0%) 14-20 days after first dose, 87.9% (95% CI, 51.7%-97.0%) 21-27 days after first dose, and 96.0% (95% CI, 82.2%-99.1%) 7 or more days after second dose. Unvaccinated HCWs remain a concern in the context of the pandemic emergency.